Introduction
The absorbed dose distribution is usually not uniform in the target volume (see Section 2.2.1). However, for the purpose of treatment reporting a nominal absorbed dose, which will be called target absorbed dose, has to be selected. The use of the expression "tumor dose" is no longer recommended.
The maximum and minimum target absorbed doses alone or together can not as a rule be used for reporting since they are not always representative of the dose distribution. Although local tumor control depends on the minimum dose to the malignant cell population, the use of the minimum target absorbed dose alone can not be recommended, since difficulties in determining the extent of the malignancy may reduce its clinical significance and further may lead to ambiguity in its definition.
The mean, median and modal target absorbed doses can not be generally recommended since they usually require a complete computerized dose plan, which may be available only for a limited number of patients and/ or hospitals.
The absorbed dose selected for reporting should be chosen to be representative of the dose distribution in the target volume, and its calculation should, if possible, not necessitate special computation facilities.
It should be stressed that target absorbed dose, as specified in the tollowing paragraphs, represents a minimum requirement for reporting, often carrying limited radiobiological and clinical information.
Finally, the specification of target absorbed dose for reporting depends on the treatment technique, and its significance can only be interpreted when information on the irradiation technique has been given.
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Description of Technique
Necessary information: a. Radiation quality I. for conventional (100-300 kV) or low energy (< 100 kV) x rays, the accelerating potential (kV) and HVL, 2. for gamma rays, the radionuclide (element and mass number), 3. for high energy x rays, the equivalent accelerating potential (MV) and the type of machine, 4. for electron beams, the energy (Me V) and type of machine. b. The number and arrangement of the beams. Indication of SSD or SAD. The description of the beam arrangement of external beam therapy should always be done in relation to the patient. c. Field sizes: geometrical field sizes which usually correspond to the 50% isodose curve. For fixed SSD, the field sizes are usually given at the skin; for fixed SAD (isocentric arrangement) the field sizes are given at the isocenter. For any field, its size in the planned section should be given first. d. Beam modification devices (wedges,. shielding blocks, etc.). e. Beam weighting. State whether this is defined in terms of the ratio of peak (applied) absorbed doses for the single beams, or in terms of the ratio of doses delivered at a defined point in the target, such as the isocenter or the "specification point" (see Section 3.3.4). To avoid ambiguity, the meaning of beam weighting should always be made clear. f. Corrections for tissue heterogeneity (state whether performed or not). g. Patient positioning.
Optional information: h. Absorbed dose distribution (isodose pattern).
i. "In vivo" absorbed dose measurements. The point at which the target absorbed dose should be stated (e) is located at the central axis at the center of the target volume. In this particular case, the relative target absorbed dose to be stated is 103%. • = demonstrated tumor; ~ = target area. and in 2 parallel planes 7 cm above (section 1) and below (section 3). In each section the border of the target area is indicated by the thick dotted line. The point at which the target absorbed dose should be stated is located at the intersection of the central axes of the 4 beams. The absorbed doses in the different sections are expressed in percentage of that dose level in the principal plane. The weighting factors indicated in the table correspond to the contribution of each beam to the target absorbed dose. The target absorbed dose to be reported for section 2 is 100%. For sections 1 and 3, the absorbed doses at the intersections of the beam axes are 87% and 94%, respectively.
Specification of Target
Specification of Target Absorbed Dose
SAD Size
cm cm x cm 100 10 x 10 100 8xl0
Treatment of a lesion of the tongue and the floor of the mouth (the border of the target area being indicated by the thick dotted line) with two wedged 8 MV x-ray beams. The point at which the target absorbed dose should be stated is located at the intersection of the central axes. The absorbed dose level at this point is defined as 100%, and is also indicated by the symbol B. Almost the whole target area is confined within the 95% isodose curve. The 50% isodose curve is also shown.
The left parotid and sub-maxillary glands were considered to be organs at risk, and their positions are indicated in the section by the broken line. The spinal cord receives less than 10%. Note that the two beams have different wedge filters and also different weighting factors (Modified from: Van der Laarse, 1976.) 
Moving Beam Therapy
For complete rotation the point at which the target absorbed dose should be stated should be in the principal plane at the center of rotation. The same recommendation applies when the arc of rotation is less than 360° but at least 270° (Figure 3.6) .
For smaller arcs (Figure 3. 7) the target absorbed dose should be stated in the principal plane, first, at the center of rotation and second, at the center of the target area. The irradiation parameters are usually chosen in such a way that the absorbed dose in the center of the target area is close to the maximum target absorbed dose. For the chosen arc, the maximum absorbed dose is not obtained at the axis of rotation, and for reporting purposes it is recommended that the absorbed dose be indicated at the center of rotation and at the cenier of the target area. In this particular patient the absorbed dose at the center of the target area is 117% of the absorbed dose at the center of rotation. The border of the target area is indicated by the thick dotted line.
3.6. Treatment of an esophageal lesion by moving beam technique (300°) with 8 MV x-rays. The point at which the target absorbed dose should be stated is located at the isocenter. The relative absorbed dose at that point is 100%. The target area is located within the 95% isodose curve. When correcting for tissue heterogeneity the lung was assumed to have a bulk density of 350 kg m-3 • The spinal cord receives an absorbed dose ranging from 40% to 20% of that at the isocenter. The border of the target area is indicated by the thick dotted line. a
Electron Therapy
The energy of the electron herun is generally chosen so that an isodose curve of at least 80% of the peak absorbed dose encloses the target area. The stated target absorbed dose should be the maximum target absorbed dose; the absorbed dose in the center of the target area is usually close to this value (Figure 3.8) . Fig. 3.8(a) . Electron treatment (15 Me V) of the internal mammary lymph nodes. No correction for tissue heterogeneity. The target absorbed dose to be reported is the maximum absorbed dose in the central beam (100%). Because of the flatness of the electron depth dose curve in the region of its maximum, 100% may be found at many points which can not be displayed by an isodose curve. Therefore, 100% is not indicated in the figure. In the example chosen here, an absorbed dose close to 100% is found at the center of the target area. 
Complex Treatments: General Recommendations
There are some situations where the above-mentioned recommendations may not apply. Such are for example a. coplanar beruns whose central rays do not intersect at one point (Figures 3.9, 3 .10, and 3.11), or intersect at a point outside the patient (Figure 2. 2 (b) .IV). b. non-coplanar berun treatments (Figure 3.9 ), c. opposed non-coaxial beams (Figures 3.9 and 3.11), d. different target volumes (Figure 3.9 ), e. modification in the treatment technique. It is recommended that one or more "specification points" be defined for the above-mentioned situations, each having a meaningful relation to the target volume and/ or the irradiation beams. The proper choice of one or more points is facilitated by an isodose presentation. When reporting, information should be given on the position of the specification point(s). The stated target absorbed dose should be expressed as a percentage of the absorbed dose at one or more of these points (Figure 3 .12). Where more than one target volume is involved, more than one specification point is usually necessary (Figure 3.9 ). When treatment has to he modified, new specification point(s) may have to he chosen with corresponding absorbed dose calculations being carried out. Note: The situations mentioned in Sections 3.3.1, 3.3.2, and 3.3.3 can, if preferred, he dealt with ·as complex treatments using specification points.
For these treatment plans, even if complete absorbed dose distributions are not computed for each particular patient, it is assumed that a basic or model dose distribution is available, either from the srune radiotherapy center or from a collection (such as an atlas; IAEA, 1978) produced elsewhere.
Additional Recommendations
If the absorbed dose in the target volume varies by more than ± 10% of the stated target absorbed dose, then the maximum (Section 2.2.2) and the minimum (Section 2.2.3) target absorbed dose should also be given. Multiplane calculations may he necessary.
Any hot spot should be reported (see Section 2.2.7). The value of the absorbed dose of the hot spot to be reported should be that of the isodose curve that encloses an area of 2 cm 2 , not the absolute maximum value.
For organs at risk the maximum absorbed dose should be given and the runount of the organ involved stated (e.g., IO cm of the spinal cord, the upper half of the left kidney).
Any other additional information considered to carry relevant radiohiological and/or clinical information should be reported.
Note I: In an isodose plan the value of each isodose curve should, if possible, be written at the higher absorbed dose side of the curve. Note II: The isodose plans shown in this report were generated in clinical routine work in several different centers and were only slightly edited for simplicity in layJout. They show different ways of presenting dosedistributions. It is not felt that recommendations should be given at this time for presentation of isodose distributions, but the reading of such a presentation is facilitated if the isodose curve through the specification point (see Section 3.3.4) is given the value 100%. Fig. 3 .9. Dose plan in 3 sections for the treatment of medulloblastoma with two target volumes (a/the demonstrated cerebellar tumor, and b/the whole subdural space and the ventricular .system) with coplanar beams whose central rays do not intersect at one point, noncoplanar beams, and opposed noncoaxial beams. The weighting of the beams was chosen to give the total absorbed dose in the two target volumes with the same number of fractions. The distribution of the absorbed dose is calculated for first, the demonstrated tumor and the cranial subdural space down to the second cervical vertebra in a frontal section (I), second, for the spinal subdural space in a median sagittal section (II) from the second cervical vertebra to the second sacral vertebra, and thirdly in a transverse section (III) through the kidneys. The cranial subdural space is treated with two opposed and the spinal subdural space with two adjacent 6()Co beams to a target absorbed dose of 30 Gy. The cerebellar tumor is further treated with two smaller opposed 6()Co beams to a total of 40 Gy. For reporting, three different specification points are chosen for the two target volumes, namely one (e) for the demonstrated cerebellar tumor and two C• and•) for the whole subdural space and the ventricular system. Fig. 3.10 . Treatment of a thyroid carcinoma with mediastinal involvement with coplanar beams whose central rays do not intersect at one point. The purpose of treatment was to deliver 50 Gy to the upper mediastinum at mid-diameter (specification point, indicated by the symbol ®. The 25 MV x-ray beam was necessary tr boost the absorbed dose to the caudal part of the target area and the 9 Me V electron beam to boost the absorbed dose to the cranial part of the target area. It was decided to keep the spinal cord absorbed dose below 42 Gy. The border of the target area is indicated by the dotted line. The figures at the isodose curves indicate absolute absorbed dose. Fig. 3.12 . Dose plan for the sagittal section in mantle treatment, showing isodose distribution and absorbed dose pattern along the hypopharynx and the esophagus. The relatively short diameter in the neck region is compensated for by an individual copper filter which has been constructed to correspond to the lined area. This contour compensating filter is placed at the collimator in addition to the general beam flattening filter used for this technique. The specification point (e) is located on the central axis midway between the beams. The absorbed dose at this point is 150% of peak absorbed dose at the central axis of either beam. In this particular patient the minimum target absorbed dose was considered to be of particular importance, being located at the most cranial and most caudal part of the target area <•> and being 90% of the absorbed dose at the specification point. IW = target area.
